The panorama of familial hypercholesterolemia in Latin America: a systematic review
2016; Elsevier BV; Volume: 57; Issue: 12 Linguagem: Inglês
10.1194/jlr.r072231
ISSN1539-7262
AutoresRoopa Mehta, Rafael Zubirán, Alexandro J. Martagón, Alejandra Vázquez-Cárdenas, Yayoi Segura-Kato, Marı́a Teresa Tusié-Luna, Carlos A. Aguilar‐Salinas,
Tópico(s)Health and Medical Research Impacts
ResumoThe burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement) of FH in LA countries. The epidemiology, genetics, screening, management, and unique challenges encountered in these countries are discussed. Published reports discussing FH in Hispanic or LA groups was considered for analysis. Thirty studies were included representing 10 countries. The bulk of the data was generated in Brazil and Mexico. Few countries have registries and there was little commonality in FH mutations between LA countries. LDL receptor mutations predominate; APOB and PCSK9 mutations are rare. No mutation was found in an FH gene in nearly 50% of cases. In addition, some country-specific mutations have been reported. Scant information exists regarding models of care, cascade screening, cost, treatment effectiveness, morbidity, and mortality. In conclusion, FH is largely underdiagnosed and undertreated in the LA region. The genetic admixture with indigenous populations, producing mestizo's groups, may influence the mutational findings in Latin America. Potential opportunities to close gaps in knowledge and health care are identified. The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement) of FH in LA countries. The epidemiology, genetics, screening, management, and unique challenges encountered in these countries are discussed. Published reports discussing FH in Hispanic or LA groups was considered for analysis. Thirty studies were included representing 10 countries. The bulk of the data was generated in Brazil and Mexico. Few countries have registries and there was little commonality in FH mutations between LA countries. LDL receptor mutations predominate; APOB and PCSK9 mutations are rare. No mutation was found in an FH gene in nearly 50% of cases. In addition, some country-specific mutations have been reported. Scant information exists regarding models of care, cascade screening, cost, treatment effectiveness, morbidity, and mortality. In conclusion, FH is largely underdiagnosed and undertreated in the LA region. The genetic admixture with indigenous populations, producing mestizo's groups, may influence the mutational findings in Latin America. Potential opportunities to close gaps in knowledge and health care are identified. Familial hypercholesterolemia (FH) is a syndrome that causes defective clearance of LDL cholesterol (LDL-C) and results in premature coronary heart disease (CHD) (1.Singh S. Bittner V. Familial hypercholesterolemia–epidemiology, diagnosis, and screening.Curr. Atheroscler. Rep. 2015; 17: 482-485Crossref PubMed Scopus (0) Google Scholar, 2.Najam O. Ray K. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management.Cardiol. Ther. 2015; 4: 25-38Crossref PubMed Google Scholar, 3.Benn M. Watts G. Tybjærg-Hansen A. Nordestgaard B. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.Eur. Heart J. 2016; 37: 1384-1394Crossref PubMed Scopus (242) Google Scholar). Two forms have been reported: autosomal dominant and autosomal recessive. The vast majority of cases have the autosomal dominant pattern of inheritance with 90% penetrance. Autosomal dominant FH is attributed to mutations in three different genes: LDL receptor (LDLR), APOB, and proprotein convertase subtilisin/kexin type 9 (PCSK9) (1.Singh S. Bittner V. Familial hypercholesterolemia–epidemiology, diagnosis, and screening.Curr. Atheroscler. Rep. 2015; 17: 482-485Crossref PubMed Scopus (0) Google Scholar, 3.Benn M. Watts G. Tybjærg-Hansen A. Nordestgaard B. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.Eur. Heart J. 2016; 37: 1384-1394Crossref PubMed Scopus (242) Google Scholar, 4.Medeiros A. Alves A. Bourbon M. Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement.Genet. Med. 2016; 18: 316-324Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar, 5.Nordestgaard B. Chapman M. Humphries S. Ginsberg H. Masana L. Descamps O. Wiklund O. Hegele R. Raal F. Defesche J. et al.Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society.Eur. Heart J. 2013; 34: 3478-3490aCrossref PubMed Scopus (1556) Google Scholar). Other FH genes have been searched for using exome sequencing without success (2.Najam O. Ray K. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management.Cardiol. Ther. 2015; 4: 25-38Crossref PubMed Google Scholar). FH caused by mutations in LDLR adaptor protein (LDLRAP) is known as autosomal recessive FH (2.Najam O. Ray K. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management.Cardiol. Ther. 2015; 4: 25-38Crossref PubMed Google Scholar). FH is the most common monogenic disorder leading to premature CHD; despite this fact, it is notoriously underdiagnosed and undertreated worldwide (6.Rynkiewicz A. Cybulska B. Banach M. Filipiak K. Guzik T. Idzior-Waluś B. Imiela J. Jankowski P. Kłosiewicz-Latoszek L. Limon J. et al.Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum.J. Clin. Lipidol. 2013; 7: 217-221Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar). Homozygous FH (HoFH) is characterized by extremely high levels of LDL-C (460–1,160 mg/dl) and early onset coronary artery disease (typically by the second decade of life) (7.Farnier M. Bruckert E. Severe familial hypercholesterolaemia: current and future management.Arch. Cardiovasc. Dis. 2012; 105: 656-665Crossref PubMed Scopus (0) Google Scholar). Mean LDL-C concentration in untreated patients is close to 615 mg/dl (7.Farnier M. Bruckert E. Severe familial hypercholesterolaemia: current and future management.Arch. Cardiovasc. Dis. 2012; 105: 656-665Crossref PubMed Scopus (0) Google Scholar, 8.Vogt A. The genetics of familial hypercholesterolemia and emerging therapies.Appl. Clin. Genet. 2015; 8: 27-36Crossref PubMed Google Scholar). Patients are classified into two groups based on the level of LDLR activity, either 90, 5, and 190 mg/dl), the presence of xanthomas (tendinous/tuberous), corneal arcus ( 95th percentile for age and sex and autosomal transmission17 HeFHHoFH 34100% HoFHHoFH 610.2HoFH 545.21 HoFH22.Alberto F. Figueiredo M. Zago M. Araújo A. Dos-Santos J. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil.Braz. J. Med. Biol. Res. 1999; 32: 739-745Crossref PubMed Google ScholarHeFH and HoFHFH cohort (probands and relatives)(Ribeirao Preto)59 from 31 families (includes 10 families reported previously)4–69NR17.2% HeFH (n = 10)8.6% HeFH (n = 5)HeFH range (197–529.8)HeFH (range 135-464)30% with Lebanese allele (n = 17) + 1 case with 4 kb deletion of the LDL-R exon 12-14Total cholesterol and LDL-C >95th percentile for age and sex58 HeFH100% HoFH100% HoFHHoFH 610.2HoFH 545.21 HoFH23.van de Kerkhof L. Van Eijk S. Defesche J. Dos-Santos J. Identification of a new mutation, S305C, in exon 7 of the low-density lipoprotein receptor gene in a Brazilian family with homozygous familial hypercholesterolemia.Genet. Test. 2003; 7: 77-79Crossref PubMed Scopus (0) Google ScholarHoFHCase report (Ribeirao Preto)122100%Cardiac catheterizationNR678323Compound heterozygote for Lebanese allele exon 14 and c.977C>G exon 7Total cholesterol and LDL-C >95th percentile for age and sex24.Salazar L. Hirata M. Cavalli S. Nakandakare E. Forti N. Diament J. Giannini S. Bertolami M. Hirata R. Molecular basis of familial hypercholesterolemia in Brazil: identification of seven novel LDLR gene mutations.Hum. Mutat. 2002; 19: 462-463Crossref PubMed Google ScholarHeFHProbands and controls35 cases/200 controlsHeFH 50 ± 1928.6% (n = 10)57% (n = 20)71%363.5 ± 62294 ± 6622 of 35 subjects with LDLR mutations (63%)Total cholesterol >360 mg/dl for age 40+ (or 270 mg/dl in youth) (87.Williams R. Hunt S. Schumacher M. Hegele R. Leppert M. Ludwig E. Hopkins P. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.Am. J. Cardiol. 1993; 72: 171-176Abstract Full Text PDF PubMed Scopus (412) Google Scholar)59% in mutation positive subjects (n = 13)25.Rocha V. Chacra A. Salgado W. Miname M. Turolla L. Gagliardi A. Ribeiro E. Rocha R. Avila L. Pereira A. et al.Extensive xanthomas and severe subclinical atherosclerosis in homozygous familial hypercholesterolemia.J. Am. Coll. Cardiol. 2013; 61: 2193Crossref PubMed Scopus (9) Google ScholarHoFHCase report120100%100% two stents in left anterior descending arteryTendon xanthomas785710LDLR exon 11 homozygous A540TDLCN26.Barros M. Ferreira-Fernandes H. Barros I. Barbosa A. Pinto G. A case of severe carotid stenosis in a patient with familial hypercholesterolemia without significant coronary artery disease.Case Rep. Cardiol. 2014; 2014: 853921PubMed Google ScholarHeFHCase report146100%Severe carotid stenosisTendon and planar xanthomas554NRNRDLCN27.Jannes C. Santos R. de Souza Silva P. Turolla L. Gagliardi A. Marsiglia J. Chacra A. Miname M. Rocha V. Filho W. et al.Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects.Atherosclerosis. 2015; 238: 101-107Abstract Full Text Full Text PDF PubMed Scopus (56) Google ScholarHeFH and HoFHFH cohort248 index cases (IC) (125+, 123-)52.7 IC mutation+40.8% IC mutation +12% IC mutation+6.4% IC mutation +403 ± 84 IC mutation +323 ± 85 IC mutation +IC: 108 LDLR (97.2%) and 2 in APOB (2.8%)LDL-C >210 mg/dl in adults and >170 mg/dl in children394 relatives (234+, 160-)43.9 relatives mutation+40.2% relatives mutation+11.1% relatives+2.6% relatives mutation+362 ± 77 relatives mutation+288 ± 79 relatives mutation+(Exon 26: Arg3527Gln Arg 3558Cys)(10 homozygotes: 8 IC and 2 relatives)28.Santos R. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?.Atheroscler. Suppl. 2014; 15: 19-25Abstract Full Text Full Text PDF PubMed Google ScholarHoFHReview of HoFH14 probandsNRNRNRNRNRNRHomozygous mutations in LDLRLDL-C levels, clinical phenotype and mutational analysisIncludes LDLR mutation A540T on exón 1129.Pereira C. Miname M. Makdisse M. Kalil Filho R. Santos R. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia.Arq. Bras. Cardiol. 2014; 103: 118-123PubMed Google ScholarHeFHHeFH cohort2025135%28.2%20.3%33525790.6% in LDLRDLCN or mutational analysis 195 with definitive diagnosis24.6% CHDNo APOB or PCSK9 mutations18.2% without CHDChile31.Arteaga Ll. A. Cuevas M.A. Rigotti R.A. González F. Castillo S. Mata L.P. Alonso K.R. Hipercolesterolemia familiar heterocigota: diagnóstico molecular y terapia combinada. Caso clínico.Rev. Med. Chil. 2007; 135: 216-220. SpanishCrossref PubMed Google ScholarHeFHCase report146100%0Tendon xanthomas: hands and ankles524NRLDLR G545ALDL-C levels and mutational analysis32.Huijgen R. Stork A. Defeschea J. Petera J. Alonso R. Cuevas A. Kastelein J. Durand M. Stroes E. Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis.Clin. Genet. 2012; 81: 24-28Crossref PubMed Scopus (0) Google ScholarHeFHCase report124.5100%Thickening of carotid artery on ultrasoundTendon xanthomas: hands and ankles270184LDLR Cys95GlyLDL-C levels and mutational analysisCosta Rica33.Thiart R. Loubser O. de Villiers J. Santos M. Kotze M. Novel stop mutation causing familial hypercholesterolemia in a Costa Rican family.Mol. Cell. Probes. 1997; 11: 457-458Crossref PubMed Scopus (3) Google ScholarHeFHCase report2 probands in same familyNRNRNRNRNRNRLDLR c.2056G>TNR34.Kotze M. Thiart R. Loubser O. de Villiers J. Santos M. Vargas M. Peeters A. Mutation analysis reveals an insertional hotspot in exon 4 of the LDL receptor gene.Hum. Genet. 1996; 98: 476-478Crossref PubMed Scopus (8) Google ScholarFHCase report1NRNRNRNRNRNRLDLR c.681-699dup (18 bp)NRCuba35.Pereira E. Ferreira R. Hermelin B. Thomas G. Bernard C. Bertrand V. Nassiff H. Del Castillo D. Bereziat G. Benlian P. Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana.Hum. Genet. 1995; 96: 319-322Crossref PubMed Scopus (0) Google ScholarHeFHThree families with HeFH (cascade screening)16 probands from 3 families38 ± 2043%6% (n = 1)75% (n = 12)382.8324.4LDLRLDL-C levels and mutational analysisVal408Met-(Afrikanar mutation)Glu256Lys Va1776MetHonduras36.Yu L. Heere-Ress E. Boucher B. Defesche J. Kastelein J. Lavoie M. Genest Jr, J. Familial hypercholesterolemia. Acceptor splice site (G→C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G→C].Atherosclerosis. 1999; 146: 125-131Abstract Full Text Full Text PDF PubMed Scopus (0) Google ScholarHoFHCase report138100%Severe coronary artery disease and bilateral carotid stenosisTendon xanthomas and xanthelasmaNR425LDLR intron 7 1061(-1)G>C (skipping of exon 8)LDL-C levels and clinical phenotypeMéxico37.Canizales-Quinteros S. Aguilar-Salinas C. Huertas-Vázquez A. Ordóñez-Sánchez M. Rodríguez-Torres M. Venturas-Gallegos J. Riba L. Ramírez-Jimenez S. Salas-Montiel R. Medina-Palacios G. et al.A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia.Hum. Genet. 2005; 116: 114-120Crossref PubMed Scopus (16) Google ScholarARH (LDL receptor adaptor protein mutation)Case report2 cases in 1 family20- and 27-year-old siblings50%NRTendon xanthomas677NRARH IVS4+2T>GLDL-C levels and mutational analysis65538.Martinez L. Ordoñez Sanchez M. Letona R. Olvera Sumano V. Miguel Guerra M. Tusie-Luna M. Aguilar-Salinas C. Hipercolesterolemia familiar homocigota por la mutación c2271delT del gen del receptor LDL, detectada únicamente en mexicanos.Gac. Med. Mex. 2011; 147: 525-527Google ScholarHoFHCase report1180%Aortic valvulopathyTendon and tuberous xanthomas519463LDLR c2271delTLDL-C levels, clinical phenotype and mutational analysis39.Magaña Torres M. Mora-Hernández S. Vázquez Cárdenas N. González Jaimes A. Homozygous familial hypercholesterolemia: the c.1055G>A mutation in the LDLR gene and clinical heterogeneity.J. Clin. Lipidol. 2014; 8: 525-527Abstract Full Text Full Text PDF PubMed Google ScholarHoFHCase report18100%Bilateral atheromatous carotid disease with severe stenosis (52%) of the left internal carotid arteryTendon and planar xanthomas782715LDLR Cys352TyrLDL-C levels, clinical phenotype and mutational analysis40.Vaca G. Vàzquez A. Magaña M. Ramìrez M. Dàvalos I. Martìnez E. Marìn B. Carrillo G. Mutational analysis of the LDL receptor and APOB genes in Mexican individuals with autosomal dominant hypercholesterolemia.Atherosclerosis. 2011; 218: 391-396Abstract Full Text Full Text PDF PubMed Scopus (20) Google ScholarHeFHFH cohortHeFH51 ± 1649% (n = 29)29% (n = 17)30% (n = 18)All = 324 ± 57All = 247 ± 5521 mutations in LDLRTotal cholesterol and LDL-C >90th percentile for age and sexn = 59Mutation+ = 338 ± 57Mutation+ = 267 ± 531 mutation in APOB (Tyr3560Cys)Mutation positive = 38Mutation− = 304 ± 50Mutation− = 232 ±± 391 mutation in PCSK9 c.1850C>A (p.Ala617Asp)HoFHHoFH21 ± 1333% (n = 1)66.6%100% (n = 3)588 ± 65537 ± 663 in LDLRn = 32 of the 3 had CHDMutation positive = 341.Aguilar-Salinas C. Familial Hypercholesterolemia.Rev. Invest. Clin. 2001; 53: 254-265PubMed Google ScholarHeFHCase report and cascade screening of familyProband and 9 family members930%Atherosclerotic lesions in carotid arteriesProband and 4 family members395NRNRTotal cholesterol and LDL-C >95th percentile for age and sex42.Robles-Osorio L. Huerta-Zepeda A. Ordóñez M.L. Canizales-Quinteros S. Díaz-Villaseñor A. Gutiérrez-Aguilar R. Riba L. Huertas-Vázquez A. Rodríguez-Torres M. Gómez-Díaz R.A. et al.Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.Arch. Med. Res. 2006; 37: 102-108Crossref PubMed Scopus (28) Google ScholarHeFHFH cohort (46 IC and 68 relatives)46 ICs43.4 ± 18 Mutation +NRNR81% (n = 37)360 ± 63 Mutation+ =287 ± 62 Mutation + =17 in LDLRTotal cholesterol and LDL-C >95th percentile for age and sex and clinical phenotype17 LDLR mutation+39.2 ± 15.4 Mutation–390 ± 48 Mutation− =315 ± 46 Mutation− =25 mutation−44.3 ± 13.4325 ± 64258 ± 6543.Robles-Osorio L. Ordoñez M.L. Aguilar-Salinas C.A. Aurón-Gómez M. Tusié-Luna M.T. Gómez-Pérez F.J. Rull-Rodrigo J.A. Familial hypercholesterolemia due to ligand-defective apolipoprotein B100: first case report in a Mexican family.Arch. Med. Res. 2003; 34: 70-75Crossref PubMed Scopus (5) Google ScholarHeFHHeFH cohort30 (1 proband with mutation in APOB)47 ± 16.2 (APOB mutation + =44)13.3% (n = 4)13.3% (n = 4)100%351 ± 61 (APOB mutation += 370)374.9 ± 60.4 (APOB mutation +=300)(APOB mutation+ = Arg3500Gln)LDL-C levels >160 mg/dl, family history and clinical phenotypePanama44.Burgos A. Aguilar M. de Arias K. Visual vignette. Familial hypercholesterolemia.Endocr. Pract. 2011; 17: 154Abstract Full Text Full Text PDF PubMed Scopus (1) Google ScholarHoFHCase report17100%NRTuberous and tendon xanthomas407349NRLDL-C levels and clinical phenotypeParaguay45.Cefalù A. Barraco G. Noto D. Valenti V. Barbagallo C. Elisir G. Cuniberti L. Werba J. Libra M. Costa S. et al.Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent.Int. J. Mol. Med. 2006; 17: 539-546PubMed Google ScholarHoFHCase report (subject is of Paraguayan descent)1 subject + family280%Aortic valvulopathy carotid and coronary stenosisPlanar xanthomas714.2667LDLR homozygous mutation exón 14, g.2051delCSimon Broom criteria (SBR)Uruguay46.Esperón P. Raggio V. Stoll M. Una nueva mutación en el promotor del gen del receptor de las lipoproteínas de baja densidad asociada a hipercolesterolemia familiar en homocigosis y heterocigosis.Clin. Investig. Arterioscler. 2009; 21: 51-55Google ScholarHoFHCase report and cascade screening of family8 HeFHMean = 53.4 (range 16–83)37.5% (n = 3)12.5% (n = 1)25% (n = 2)289.4NRLDLR 47C>A (promoter region)LDL-C levels, clinical phenotype + mutational analysis in HoFH proband3 HoFH55,48,4533.3% (n = 1)66.6% (n = 2)100% (n = 3)Proband = 714Proband = 629Mea
Referência(s)